Clone:
REA816
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MC
Alternative names:
PROM1, AC133, CORD12, MCDR2, MSTP061, PROML1, RP41, STGD4

Extended validation for CD133/2 Antibody, anti-human, REAfinity™

Specificity

Epitope competition
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Other clonesOverlap in epitope recognition with REA816
293C3++
AC133-
AC141++
clone 7-
EMK08-
REA753-
REA820++
REAL233-
S16015F-
S16016B-
S16016E++
TMP4-
W6B3C1-
Cells were incubated with an excess of purified unconjugated CD133/2 (REA816) antibody followed by staining with fluorochrome-conjugated antibodies of other known clones against the same marker. Based on the fluorescence signal obtained, the clones were identified as recognizing completely overlapping (++), partially overlapping (+), or completely different epitopes (-) of the marker.

Sensitivity

Performance comparison
Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.
View details
Flow cytometric comparison of different clones for CD133/2. Human peripheral blood mononuclear cells (PBMCs) were stained with CD133/2 antibodies and with a suitable counterstaining. As a control, CD133/2 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. CD45+ cells were pregated for the analysis. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD133/2. Human peripheral blood mononuclear cells (PBMCs) were stained with CD133/2 antibodies and with a suitable counterstaining. As a control, CD133/2 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. CD45+ cells were pregated for the analysis. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD133/2. Human peripheral blood mononuclear cells (PBMCs) were stained with CD133/2 antibodies and with a suitable counterstaining. As a control, CD133/2 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. CD45+ cells were pregated for the analysis. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD133/2. Human peripheral blood mononuclear cells (PBMCs) were stained with CD133/2 antibodies and with a suitable counterstaining. As a control, CD133/2 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. CD45+ cells were pregated for the analysis. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD133/2. Human peripheral blood mononuclear cells (PBMCs) were stained with CD133/2 antibodies and with a suitable counterstaining. As a control, CD133/2 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. CD45+ cells were pregated for the analysis. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD133/2. Human peripheral blood mononuclear cells (PBMCs) were stained with CD133/2 antibodies and with a suitable counterstaining. As a control, CD133/2 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. CD45+ cells were pregated for the analysis. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD133/2. Human peripheral blood mononuclear cells (PBMCs) were stained with CD133/2 antibodies and with a suitable counterstaining. As a control, CD133/2 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. CD45+ cells were pregated for the analysis. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD133/2. Human peripheral blood mononuclear cells (PBMCs) were stained with CD133/2 antibodies and with a suitable counterstaining. As a control, CD133/2 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. CD45+ cells were pregated for the analysis. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Flow cytometric comparison of different clones for CD133/2. Human peripheral blood mononuclear cells (PBMCs) were stained with CD133/2 antibodies and with a suitable counterstaining. As a control, CD133/2 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. CD45+ cells were pregated for the analysis. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Fixation data
To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.
No fixation
Post fixation
View details
Comparison of staining pattern on non-fixed and fixed cells using CD133/2 (REA816). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
View details
Comparison of staining pattern on non-fixed and fixed cells using CD133/2 (REA816). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
Comparison of staining pattern on non-fixed and fixed cells using CD133/2 (REA816). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD133/2 Antibody, anti-human, REAfinity™

Overview

Clone REA816 recognizes epitope 2 of the human CD133 antigen (CD133/2). CD133 is a marker that is frequently found on multipotent progenitor cells, including immature hematopoietic stem and progenitor cells in human fetal liver, bone marrow, cord blood, and peripheral blood. CD133 has also been found to be expressed on circulating endothelial progenitor cells, tissue-specific stem cells, cancer stem cells from tumor tissues, as well as ES and iPS cell–derived cells.
Additional information: Clone REA816 displays negligible binding to Fc receptors.

Alternative names

PROM1, AC133, CORD12, MCDR2, MSTP061, PROML1, RP41, STGD4

Detailed product information

Technical specifications

CloneREA816
Clonalitymonoclonal
Isotyperecombinant human IgG1
Isotype controlREA Control Antibody (S), human IgG1
Hostcell line
Type of antibodyPrimary antibodies, Recombinant antibodies
Specieshuman
AntigenCD133/2
Alternative names of antigenPROM1, AC133, CORD12, MCDR2, MSTP061, PROML1, RP41, STGD4
Molecular mass of antigen [kDa]117
Distribution of antigenendothelial cells, epithelial cells, red blood cells, hematopoietic stem and progenitor cells, ES and iPS cells, brain, heart, kidney, liver, lung, pancreas, placenta
Entrez Gene ID8842
RRIDAB_2654900, AB_2654901, AB_2654902, AB_2654903, AB_2654904, AB_2654905, AB_2654906, AB_2751103, AB_2751087, AB_2654907, AB_2654908, AB_2801915, AB_2654899

Resources for CD133/2 Antibody, anti-human, REAfinity™

Certificates

Please follow this
link
to search for Certificates of Analysis (CoA) by lot number.

References for CD133/2 Antibody, anti-human, REAfinity™

Publications

  1. Yin, A. H. et al. (1997) AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90: 5002-5012
  2. Bühring, H. J. et al. (1999) The monoclonal antibody 97A6 defines a novel surface antigen expressed on human basophils and their multipotent and unipotent progenitors. Blood 94: 2343-2356
  3. Peichev, M. et al. (2000)
    Expression of VEGFR-2 and AC133 by circulating human CD34
    +
    cells identifies a population of functional endothelial precursors.
    Blood 95: 952-958
  4. Richardson, G. et al. (2004) CD133, a novel marker for human prostatic epithelial stem cells. J. Cell. Sci. 117: 3539-3545
  5. Bussolati, B. et al. (2005) Isolation of renal progenitor cells from adult human kidney. Am. J. Pathol. 166: 545-555
  6. Thill, M. et al. (2004)
    Identification of a population of CD133
    +
    precursor cells in the stroma of human cornea.
    Invest. Ophthalmol. Vis. Sci. 45: 3519
  7. Pfenninger, C. V. et al. (2007) CD133 is not present on neurogenic astrocytes in the adult subventricular zone, but on embryonic neural stem cells, ependymal cells, and glioblastoma cells. Cancer Res. 67: 5727-5736
  8. Hawley, R. G. et al. (2006) Hematopoietic stem cells. Meth. Enzymol. 419: 149-179
  9. Balasubramanian, P. et al. (2012) Multiparameter analysis, including EMT markers, on negatively enriched blood samples from patients with squamous cell carcinoma of the head and neck. PLoS One 7(7)
  10. Donnenberg, A. D. et al. (2013) KIT (CD117) expression in a subset of non-small cell lung carcinoma (NSCLC) patients. PLoS One 7(12): e52885
  11. Kurian, L. et al. (2013) Conversion of human fibroblasts to angioblast-like progenitor cells. Nat. Methods 10(1): 77-83
  12. Walton, R. M. et al. (2013)
    Postnatal neural precursor cell regions in the rostral subventricular zone, hippocampal subgranular zone and cerebellum of the dog (
    Canis lupus familiaris
    ).
    Histochem. Cell Biol. 139(3): 415-429
  13. Kang, T. W. et al. (2014) Growth arrest and forced differentiation of human primary glioblastoma multiforme by a novel small molecule. Sci Rep 4: 5546

Related products for
CD133/2 Antibody, anti-human, REAfinity™

3 products available

Seems like you are coming from USA!
Do you want to visit our website in your country?